Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (NASDAQ: REVB) is a clinical-stage life sciences company developing Gemini, a proprietary PHAD®-based toll-like receptor 4 (TLR4) agonist designed to rebalance the innate immune response in acute and chronic inflammation-driven diseases. The REVB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow key scientific, clinical, regulatory, and corporate developments.
News about Revelation Biosciences frequently highlights progress across its Gemini programs for acute kidney injury (GEMINI-AKI), chronic kidney disease (GEMINI-CKD), prevention of post-surgical infection (GEMINI-PSI), and treatment of severe burn-related hyperinflammation (GEM-PBI). Updates include clinical milestones such as Phase 1 and Phase 1b data from the PRIME study in stage 3 and 4 CKD patients, where the company has reported safety, reductions in inflammatory activity, and restoration of normal cellular responses to stimuli.
Investors and observers can also find announcements about interactions with the U.S. Food and Drug Administration, including submission and acceptance of an end-of-phase 1 meeting package for Gemini in AKI, as well as manufacturing news such as the start of GMP production of Gemini and placebo to support later-stage randomized, double-blinded, placebo-controlled trials.
Beyond clinical and regulatory updates, the REVB news stream covers financial and corporate actions disclosed by the company, including warrant exercise inducement transactions, special meetings of stockholders to approve share issuances under Nasdaq rules, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Bookmark this page to monitor Revelation Biosciences’ ongoing disclosures about Gemini’s development, capital markets activity, and governance events.
Revelation Biosciences (NASDAQ:REVB) will implement a 1-for-4 reverse stock split effective the morning of January 28, 2026. Post-split shares will begin trading that day under the existing symbol REVB and a new CUSIP 76135L804 will apply. The reverse split is intended to increase the share price to regain compliance with The Nasdaq Capital Market's minimum bid continued listing requirement. Proportionate adjustments will be made to warrants, restricted stock units and stock options. Fractional shares resulting from the split will be rounded up to the nearest whole share.
Revelation Biosciences (NASDAQ:REVB) entered a definitive agreement for immediate exercise of outstanding warrants to purchase up to 13,065,000 common shares at a reduced exercise price of $0.86 per share, generating roughly $11 million in gross proceeds. Closing is expected on or about January 26, 2026, subject to customary conditions. In exchange, exercising holders will receive new Class J warrants exercisable into up to 26,130,000 shares at $0.86 per share, exercisable only after stockholder approval and for a five-year term thereafter. The company will file a resale registration on Form S-3 within 20 days of closing.
Revelation Biosciences (NASDAQ:REVB) said it reached agreement with the FDA on an approval pathway for Gemini to treat Acute Kidney Injury (AKI). The agency agreed that a single adaptive Phase 2/3 randomized, double-blind, placebo-controlled study of approximately 300 patients using a clinically relevant composite primary endpoint (death and/or need for dialysis) plus positive data would be sufficient for an NDA. Revelation plans to build trial infrastructure, engage a CRO, assemble scientific advisors, manufacture clinical supply, and work to initiate the study during 2026.
Revelation Biosciences (NASDAQ:REVB) will present additional clinical data from the recently completed PRIME study on Gemini at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego.
Presented results reportedly show normalization of the hyperinflammatory state in stage 3–4 CKD patients and restoration of immunocompetence. Presenter: Robin Marsden, SVP Biology. Date/time: Sunday, March 29, 2026, 5:30–7:30 PM PT. Location: Manchester Grand Hyatt, San Diego.
Revelation Biosciences (NASDAQ:REVB) announced an inducement equity grant approved January 8, 2026 of 90,000 restricted stock units (RSUs) to a new non-executive employee. The RSUs were granted outside the company's stockholder-approved equity incentive plan as an inducement under Nasdaq Listing Rule 5635(c)(4). The award vests over two years in equal quarterly installments, beginning on the first quarterly vesting date after the employee's hire date, and is subject to continued service through each vesting date.
Revelation Biosciences (NASDAQ:REVB) announced the initiation of GMP manufacturing for GEMINI and matching placebo to supply later‑stage clinical studies. The manufacturing run will provide clinical drug supply needed to support randomized, double‑blind, placebo‑controlled trials and is described as a critical step toward advancing GEMINI's development and approval pathway.
The company said it is working with a leading global contract manufacturing organization and noted it met with the FDA in December 2025 to seek agency feedback on the clinical development and regulatory pathway for GEMINI as a treatment for acute kidney injury (AKI); Revelation is awaiting the FDA meeting minutes.
Revelation Biosciences (NASDAQ:REVB) announced it has reached a quorum for its Special Meeting on December 3, 2025. Shareholders who have not voted have until 11:59pm ET on December 2, 2025 to submit votes.
The company reaffirmed regulatory progress after successfully submitting and receiving acceptance of an end-of-phase 1 meeting package to FDA on November 20, 2025, and said it remains on track to hold that meeting later in 2025 to discuss the clinical and approval pathway for Gemini for acute kidney injury (AKI). The company also referenced its November 6, 2025 financial report covering the three and nine months ended September 30, 2025, highlighting top-line PRIME clinical results and $9.6 million gross proceeds from a September 2025 warrant inducement.
Revelation Biosciences (NASDAQ:REVB) submitted and had its end-of-phase 1 meeting package accepted by the FDA, and is on track to hold the meeting later in 2025 to get agency feedback on the regulatory pathway for Gemini as a treatment for acute kidney injury (AKI).
The company reported that its Phase 1b PRIME study in stage 3–4 chronic kidney disease met its primary safety and tolerability endpoint and showed reductions in inflammatory activity and restored cellular responses in PBMCs up to 168 hours post-dose. Revelation plans to initiate a later-stage clinical study in 2026 and to publish additional PRIME results while exploring other indications for Gemini.
Revelation Biosciences (NASDAQ:REVB) reported results for the three and nine months ended September 30, 2025, and disclosed corporate and cash updates.
Key points: the company announced top-line PRIME clinical study results, received $9.6 million gross from a September 2025 warrant inducement, and held $12.7 million cash as of September 30, 2025 (up from $6.5 million at December 31, 2024).
Operating highlights include $6.3 million net cash used in operating activities for the nine months ended September 30, 2025 (down from $14.6 million in 2024), a Q3 2025 net loss of $1.9 million (loss per share $(1.77)), and a nine‑month net loss of $6.4 million (loss per share $(9.76)). The company expects cash to fund operations through Q3 2026 and plans to meet with the FDA to align on Gemini’s registration path.
Revelation Biosciences (NASDAQ:REVB) announced the cancellation of the adjourned Special Meeting of Stockholders that had been rescheduled for October 29, 2025 due to a technical difficulty that prevented stockholders from voting all of their shares.
The company set a new record date of October 29, 2025 and scheduled a new Special Meeting for December 3, 2025. Revelation will mail new proxy materials to all stockholders of record as of the new record date and urges stockholders to vote promptly upon receipt.
FAQ
What is the current stock price of Revelation Biosciences (REVB)?
What is the market cap of Revelation Biosciences (REVB)?
